ReviewPeerJ2025
NLRP3 inflammasome and pyroptosis: implications in inflammation and multisystem disorders.
Review in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Protective effects ofRedox report : communications in free radical research · 2026Article
- Doxorubicin-induced hepatotoxicity: a multifaceted pathogenesis from mitochondrial collapse to immune remodeling and epigenetic memory.Archives of toxicology · 2026Review
- Review
- Article
- The role of NLRP3 inflammasome in the development of postoperative ileus and its molecular mechanism in male mice.Physiological reports · 2026Article
- A pH-responsive layered double hydroxide nanoradiosensitizer for bone metastasis tumor.Materials today. Bio · 2026Article
- Advances in understanding the dual roles of testicular immune responses: From immune privilege to inflammation.Seminars in immunopathology · 2026Review
- Interconnected cell death pathways: central mechanisms and therapeutic targets in impaired follicular development of polycystic ovary syndrome.Journal of ovarian research · 2026Review
- Article
- Neuroprotective effect of sinomenine on parkinson's disease through NLRP3/Caspase-1/GSDMD pathway-mediated pyroptosis inhibition.Metabolic brain disease · 2026Article
- Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects.Frontiers in cell and developmental biology · 2026Review
- Qijia Rougan Formula alleviates liver fibrosis by inhibiting NLRP3-mediated pyroptosis and regulating macrophage polarization.Frontiers in immunology · 2026Article
- Electroacupuncture alleviates myocardial ischemia-reperfusion injury by targeting and inhibiting NLRP3 inflammasome-mediated cardiomyocyte pyroptosis via serum exosomal miR-22-3p.Frontiers in immunology · 2026Article
- Targeting gasdermin D-mediated pyroptosis: a precision anti-inflammatory strategy for acute and chronic lung diseases.Inflammopharmacology · 2026Review
- Cell death in sepsis: unveiling new perspectives on organ dysfunction.Frontiers in cell and developmental biology · 2026Review
- Beyond pathogens: a narrative review of the immunological nexus of damage-associated molecular patterns and inflammasome activation in sterile AECOPD.Frontiers in immunology · 2026Review
- Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NLRP3 inflammasome is a multiprotein complex that senses diverse pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), activating the pyroptosis pathway. Pyroptosis is a form of programmed cell death that plays a crucial role in immune responses and inflammatory processes. The NLRP3 inflammasome-gasdermin D (GSDMD) axis has emerged as a critical therapeutic target in inflammatory diseases. Oligomerization of NLRP3 triggers caspase-1 activation, which subsequently induces GSDMD palmitoylation-an essential event that facilitates pyroptosis. Clinically, NLRP3 inhibitors, such as MCC950, demonstrate protective effects in NLRP3-mediated inflammatory diseases. GSDMD holds substantial potential as a diagnostic, monitoring, and therapeutic target across diverse diseases, underscoring its utility as a pan-biomarker. This review aims to synthesize current knowledge regarding the structure and function of the NLRP3 inflammasome and the regulatory mechanisms governing pyroptosis. Additionally, integrating findings from multiple physiological systems highlights the key roles of the NLRP3 inflammasome and pyroptosis in disease pathogenesis, offering novel perspectives for targeting inflammatory responses and associated disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.